10
Participants
Start Date
July 1, 2017
Primary Completion Date
March 15, 2019
Study Completion Date
March 15, 2019
"Raltegravir and Zidovudine"
Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
Instituto de Medicina Tropical Alexander von Humboldt, Lima
Merck Sharp & Dohme LLC
INDUSTRY
Universidad Peruana Cayetano Heredia
OTHER